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Downregulation of miR-33b has been documented in many types of cancers and is
being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT).
Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of
controlling the stem cell differentiation and the cell proliferation processes. We aim to
evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC)
and to analyze the role of EZH2 in this process as well as the interaction between them.
miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has
an opposite expression in vitro and in patients’ samples. The upregulation of miR-33b
suppressed proliferation, induced apoptosis, reduced invasion, migration and regulated
EMT by an increase of E-cadherin and a decrease of ß-catenin and vimentin. The
silencing of EZH2 mimicked the impact of miR-33b overexpression. Furthermore, the
inhibition of miR-33b induces cell proliferation, invasion, migration, EMT, and EZH2
expression in non-tumorigenic cells. Importantly, the Kaplan–Meier analysis showed a
significant association between high miR-33b expression and better overall survival.
These results suggest miR-33b as a suppressive miRNA that could inhibit tumor
metastasis and invasion in HER2+ BC partly by impeding EMT through the repression
of the MYC–EZH2 loop.
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INTRODUCTION
Breast cancer (BC) is the most frequently diagnosed malignancy among women worldwide
and considered as the most threatening cancer for women’s health (1). Breast cancer mortality
still accounted for about 25.3 per 100,000 women in 2018 (2). During the recent years, to
better understand BC biology, many efforts have been performed, leading to elucidate the
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heterogeneity of different subtypes [luminal A, luminal B,
HER2-positive (HER2+), and triple-negative] susceptible for
personalized approach and treatment. HER2 gene amplification
occurs in 20–25% of BCs and is associated with disease
relapse and poor prognosis. There are different targeted agents;
both monoclonal antibody and tyrosine kinase inhibitors have
radically changed the history of this disease (3). Nevertheless,
after a neoadjuvant or an adjuvant approach, the rate of
relapse remains substantially high (4). It is therefore essential
to explore deeply the molecular mechanisms responsible
for disease progression and therapy resistance to identify
possible biomarkers that would guide novel treatments for
this subtype of BC.
MicroRNAs are small molecules based on 20–22 nucleotides,
having a main function in regulating gene expression post-
transcriptionally by inhibiting protein translation or causing the
degradation of the target mRNA (5). Different cancer types
have a varied expression of miRNAs; in addition, some miRNAs
may function as oncogenes or tumor suppressors. They have
been directly implicated in cancer metastasis or the prevention
of cancer progression by participating in the regulation of the
epithelial–mesenchymal transition (EMT) pathway, stemness
and targeting apoptosis pathway. In this scenario, miR-33b was
found to act as an anti-cancer miRNA, inhibiting cell migration,
proliferation, and invasion in melanoma cancer (6), lung cancer
(7, 8), prostate cancer (9), osteocarcinoma (10, 11), gastric cancer
(12), and triple-negative BC (TNBC) (13). However, the role
and the action mechanism of miR-33b in HER2+ BC subtype
are still unclear.
Furthermore, the enhancer of zeste homolog 2-gene (EZH2)
has a master regulatory function in controlling processes such as
stem cell differentiation, cell proliferation, early embryogenesis,
and X chromosome inactivation (14). EZH2 is overexpressed
in metastatic prostate cancer and promotes cell metastasis and
proliferation by inhibiting apoptosis (15). It is also described as
a master regulator of the EMT by overexpressing Snail, Slug,
and vimentin and suppresses E-cadherin (CDH1) expression in
endometrial cancer and gastric cancer (16, 17), but less has been
explored in the HER2+ BC subtype. Moreover, the transcription
factor MYC (18) has been suggested as a positive regulator
of EZH2 by different mechanisms in several types of cancers.
MYC might enhance EZH2 expression through inhibiting the
microRNAs miR-26a and miR-26b (19) and also by the activation
of the EZH2 expression through binding with E-box, a DNA
binding site of MYC (20). Emerging shreds of evidence also
showed that miR-33b negatively regulates MYC in osteosarcoma
cancer (10) and prostate cancer progression (9) by directly
binding with its 3′ UTR region. Moreover, there is recent
substantial data which suggested that miR-33a could negatively
regulate EZH2 in cancer progression by direct interaction in
TNBC (21).
Taking all these information together, our paper aimed to
explore more about miR-33b from miR-33 family in HER2+ BC.
As HER2+ is an aggressive disease with significant mortality,
it requires massive molecular mechanism studies to defeat its
aggressiveness (22). Our results show, for the first time, that the
under-expression of miR-33b is related to the poor prognosis and
low survival in HER2+ BC, while a high expression of EZH2 is
directly proportional to tumor aggressiveness and proliferation.
As the miR-33b and EZH2 molecular mechanism functions have
been less elucidated in this subtype of BC, we tried to fill the
loophole between them. MiR-33b exerts its function by indirectly
targeting EZH2 through directly inhibiting MYC to repress the
migration, invasion, proliferation, and EMT development of
HER2+ BC. Furthermore, we identified a novel 33b/MYC/ EZH2
axis implicated in proliferation and invasion in HER2+ BC.
MATERIALS AND METHODS
Cell Culture and Reagents
Human BC cell lines BT474, SKBR3, MDA-MB-468, MCF7 and
MCF-12A, and MCF-10A non-tumorigenic epithelial cells were
maintained in Dulbecco’s modified Eagles medium (GIBCO)
supplemented with 10% fetal bovine serum (FBS; Gibco),
10,000 U/ml penicillin, 10,000 µg/ml streptomycin, and 1% L-
glutamine (200 mM) (×100). All cells were cultured at 37◦C in
5%-CO2 atmosphere.
Transfection
The cell lines were transfected either with 100 nM hsa-miR-33b-
5p mirVana mimic (assay ID MC12289, Ambion) or inhibitor
miRNAs (assay ID MH12289, Ambion) and 100 nM EZH2 siRNA
(#s4916, #s4918, Thermofisher), as well as negative control for
the experiments. In vitro transfections of the oligonucleotides
were performed using Lipofectamine 2000 (Invitrogen; Thermo
Fisher Scientific, Inc., Waltham, MA, United States) according
to the manufacturer’s instructions. After 6 h of transfection, the
transfection medium was replaced with a complete medium. All
the experiments were carried out at 48 and 72 h post-transfection.
RNA Extraction and Quantitative
Real-Time PCR
To detect the expression of miRNA and mRNA total RNA
was extracted using TRIZOL reagent (Invitrogen, Carlsbad, CA,
United States) according to the manufacturer’s instructions.
cDNA was synthesized from 1 µg of total RNA using a High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems)
and a TaqMan R© MiRNA Reverse Transcription kit (Applied
Biosystems, United States). Real-time-qPCR was performed with
a TaqMan R© Universal Master Mix (Applied Biosystems) and
TaqMan R© 20× assay (Applied Biosystems) by following the
manufacturer’s protocol on a quant-studio 3 and 5 real-time
PCR system (Applied Biosystem, United States). The expression
data were uniformly normalized to the internal control. For the
miRNA expression, the endogenous control was RNU43, and for
the gene expression, the endogenous control was GAPDH, and
relative gene and mi-RNA expression was quantified using the
2-11 Ct method.
Cell Invasion and Migration Assays
For the migration assay, 5 × 104 cells (72 h post-transfection)
were seeded in 200 µl of serum-free medium into the upper
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chamber of each insert (353097, Corning R©), and 700 µl of
medium supplemented with 10% FBS was added into the lower
chamber. For the cell invasion assay, the polyester membranes
of the upper surface of the insert (353097, Sigma) were
pre-coated with a matrix gel (Corning R© Matrigel R© Basement
Membrane Matrix, Ref: 356234). Following equal amount of
above mentioned transfected cells were seeded in 200 µL of
serum-free medium on the pre coated insert. The lower chamber
was supplemented with 700 µL of complete medium and
incubated at 37◦C. After 24 h, the cells that invaded and migrated
through the membrane were fixed and permeabilized with 70%
chilled ethanol for 2 min and with 100% methanol for 15 min,
respectively, at room temperature. The invaded and migrated
cells were further stained with 0.4% crystal violet for 10 min at
room temperature. The cells were then imaged and counted from
photographs of five randomly selected fields of the fixed cells.
Wound Healing Assay
To check the motility capacities of the cells after miR-33b
transfection, wound healing assay was performed. At 72 h post-
transfection, the cells were seeded in six-well plates to obtain
100% confluence in 24 h. After 24 h, the wound was induced by
scratching the monolayer with a micropipette tip, and the dish
was placed at 37◦C in a 5%-CO2 incubator chamber. Pictures
were acquired at 0 h and after 24 h using a microscope.
WST-1 Cell Proliferation
After transfection, cell proliferation was assessed using the WST
assay. A total of 3 × 103 transfected cells and negative control
cells were seeded in 96-well plates from 1 to 7 days. On each of
the mentioned days, cell proliferation was measured using WST-
reagent (ab155902, Abcam). Seven percent of the WST reagent
was added to each well with phenol red-free media. The plate
was incubated for 4 h at 37◦C. Then, absorbance was measured
at 450 nm in a microplate reader with background correction at
650 nm. The significance of any differences were assessed using
t-test.
Cell Cycle Analysis
To analyze cell cycle, 5 × 104 cells were seeded in six-well plates
for each condition in triplicates. After 48 h of transfection, the
cells were harvested by trypsin and washed with 1× phosphate-
buffered saline (PBS) twice. Then, the harvested cells were fixed
with chilled 70% ethanol and incubated at −20◦C for 6–7 h.
The cells were then centrifuged soon after washing with 1×
PBS twice, and the pellets were resuspended with propidium
iodide (PI) staining buffer (PI/RNase, IMMUNOSTEP) and
stored at 4◦C overnight. Stained cells were acquired for cell cycle
analysis by flow cytometry using a FACSVerseTM flow cytometer
(BD Bioscience, United States), and raw data were analyzed by
FlowJo software.
Apoptosis Analysis
Apoptotic cells were determined by double staining using
FITC Annexin V Apoptosis Detection Kit with PI (ANXVKF-
100T, IMMUNOSTEP) according to the manufacturer’s
recommendation. Briefly, 1 × 105 cells were seeded in a six-well
plate. After 72 h post-transfection, the supernatant medium
was taken in one tube. The attached cells were harvested by
trypsinizing and were collected into the same tube. The cells were
washed with 1× PBS twice, and the pellet was resuspended with
1× annexin binding buffer. Five microliters of annexin V-FITC
and 5 µl of PI were added to the resuspended cells and incubated
for 15 min at room temperature in the dark. Furthermore, 400 µl
of 1× binding buffer was added with DAPI (0.1 mg/ml, 1–2 µl).
The stained cells were acquired for cell cycle analysis by flow
cytometry using a FACSVerseTM flow cytometer (BD Bioscience,
United States), and raw data were analyzed by FlowJo software.
Western Blot Analysis
At the indicated time (72 h), the whole lysate of transfected
cells was extracted using Thermo ScientificTM RIPA lysis buffer
(Ref: 89900). The lysates were transferred to a clean microfuge
tube, placed on ice for 30 min, and centrifuged for 30 min at
13,000 rpm. The supernatant was transferred to a fresh microfuge
tube, and the protein concentration was determined using a
BCA protein assay kit (PierceTM BCA Protein Assay Kit, Ref:
23227). The protein lysates were separated on 10% SDS PAGE
and transferred to nitrocellulose membranes (Ref: 1620115, Bio-
Rad). The membranes were blocked in 5% BSA for 1 h and
then incubated with antibodies of E-cadherin (BD Biosciences,
#610181), ß-catenin (BD Biosciences, #610153), vimentin (BD
Biosciences, #550513), EZH2 (Cell Signaling, #1674905S), and
GAPDH (Thermo ScientificTM, #MA5-15738) overnight at 4◦C.
On the following day, the membranes were washed and
subsequently incubated with the appropriate HRP-conjugated
secondary antibodies for 1 h at room temperature. Following this
incubation, the membranes were washed and briefly incubated
with a PierceTM ECL Western Blotting Substrate western blotting
detection reagent (Thermo Fisher ScientificTM, Ref: 32106).
Clinical Samples and RNA Isolations
Formalin-fixed and paraffin-embedded samples of human BC
tissues from different subtypes of BC patients and breast samples
from healthy donors were selected to analyze the expression
of miR-33b and EZH2 gene. The total RNA was isolated from
tissue blocks using the RecoverAll Total Nucleic Acid Kit
(Ambion) for standard mRNA/miRNA analysis. One microgram
of total RNA was retro-transcribed with random primers (for
gene expression) and specific primers (for miRNA expression)
using Reverse Transcription Kit (Applied Biosystems), and 5 ng
of cDNA was used for quantitative PCR for both gene and
miRNA expression analysis. The quantitative PCR analysis was
performed as mentioned above.
TCGA Data Analysis
The expression data for miRNA-33b were obtained from Xena
browser database1 for The Cancer Genome Atlas (TCGA) BC,
which contained 1,285 cases of different BC subtypes solid
tumors and normal. From there, we were able to obtain only
211 specimens with clinical details, including luminal B (n = 49),
basal-like (n = 26), luminal A (n = 92), HER2+ (n = 18), and
normal solid tissue (n = 26). For EZH2 expression, we used
the same data base, which contained 1,248 cases of different BC
1https://xenabrowser.net/
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FIGURE 1 | Expression of miR-33b and EZH2 in HER2+ cancer cell lines, cancer patients, and non-tumorigenic cells. The relative expression of miR-33b was
determined in HER2+ cancer cell lines and HER2+ tumor tissues, non-tumorigenic epithelial cell line, and healthy controls by Q-PCR and normalized to RNU43 (for
cell lines) and miR-16 (for tissue) (A,B). EZH2 expression was determined also in the same specimen by Q-PCR and normalized to GAPDH (for cell lines), PPIA, and
MRPL19 (for tissue) (C,D). EZH2 protein expression was determined by western blot in HER2 + and MCF-10A cell line (E). Student’s t-test was used to analyze the
significant differences. *p < 0.05, ***p < 0.001, ****p < 0.0001.
subtypes solid tumors and normal, wherefrom we only obtained
522 specimens with clinical details, including luminal B (n = 127),
basal-like (n = 98), luminal A (n = 231), HER2 + (n = 58), and
normal solid tissue (n = 8). The statistical analysis was done using
Shapiro–Wilk normality test, and based on normality test results,
parametric and non-parametric tests were applied to obtain the p
value of the analysis.
In silico Survival Analysis
Overall survival associated with miRNA and gene expression
was analyzed using Kaplan–Meier plotter (KM plotter) tool2.
This tool works upon a database containing different subtypes
of BC Affymetrix microarray samples and associated survival
information, with a median follow-up of 120 months. Based
on METABRIC dataset, by specifying the miRNA name and
the gene name on the search tool and filtering down to “all
breast cancer subtypes and HER2+ subtype,” the survival rates
according to miRNA or gene expression were obtained. The
hazard ratio (HR) with 95% confidence intervals and log-rank
p-value were calculated and shown. The obtained results were
used to identify the prognostic value of miR-33b and EZH2
expressions on HER2+ BC.
Statistical Analysis
The sample and the control groups were compared using two-
tailed Student’s t-test. All data presented include median and
2http://kmplot.com/analysis/
standard deviation. P-values less than 0.05 were considered to be
statistically significant.
Ethical Approval
The study was conducted in accordance with recognized ethical
guidelines (Declaration of Helsinki), and it was approved by
the INCLIVA institutional review board (protocol number:
2018/077). All the participants in the study signed a written
informed consent.
RESULTS
Expression of miR-33b and EZH2 in
HER2+ Breast Cancer Cell Lines, Patient
Samples, and Non-tumorigenic Cells
MiR-33b expression was determined in four human BC cell lines,
including MDA-MB-468, MCF-7, BT474, and SKBR3 (HER2+),
with the non-tumorigenic epithelial cell lines MCF12A and MCF-
10A as controls. The quantitative PCR (Q-PCR) data revealed
that miR-33b expression was significantly higher in MCF-10A as
compared to that in HER2+ BC cell lines (Figure 1A). An analysis
of tissue samples from Department of Oncology, Hospital
Clinico de Valencia and the TCGA database for a HER2+ BC
retrospective cohort confirmed a significantly lower miR-33b
expression level than the breast control samples (Figure 1B
and Supplementary Figure 1E). The EZH2 expression was
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FIGURE 2 | MiR-33b reduces cell proliferation and induces early and late apoptosis. Satisfactory transfection efficiency of miR-33b mimic in both HER2 + cell lines:
BT474 (A) and SKBR3 (B). Cell proliferation was carried out through WST assay in both cell lines after transfection with miR-33b mimic until 7 days (C,D). The
apoptotic cell population was determined at 72 h in both cell lines by flow cytometry through annexin-V/PI staining (E). To confirm the apoptotic population and the
percentage of sub-G0/G1 population, cell cycle was analyzed through PI-RNAse assay at 48 h (F). Student’s t-test was used to analyze the significant differences.
*p < 0.05, **p < 0.01, ***p < 0.001.
significantly higher in HER2+ BC cell lines than in MCF-
10A as determined at the mRNA level (Figure 1C) and at
the protein level (Figure 1E). Similarly, a significantly higher
EZH2 expression was found in HER2+ BC tissue samples vs.
healthy breast tissues (Figure 1D) and also from the TCGA
data portal (Supplementary Figure 1F). The analysis of miR-
33b and EZH2 in other BC subtypes showed as well a significant
higher expression of miR-33b in control cell lines vs cancer cell
lines and an oppositely significant higher expression of EZH2
on cancer cell lines in comparison with those of the controls
(Supplementary Figures 1A,C). MiR-33b and EZH2 expression
in the TNBC patients’ samples showed the same tendency than
the HER2 + samples compared with those in healthy breast
tissues (Supplementary Figures 1B,D). These data altogether
suggested a downregulation of miR-33b and a high expression of
EZH2 in HER2+ BC subtypes both in vitro and in BC tissues,
being one of the important reasons for the high aggressiveness
of this subtype.
Overexpression of miR-33b Reduces
Proliferation and Induces Apoptosis in
HER2+ BC Cell Lines
To determine the potential effect of miR-33b on cell proliferation
and apoptosis in HER2 + BC, cells were transfected with miR-
33b mimic or scramble miR (miR-NC). Its expression was
confirmed by Q-PCR in both cell lines (Figures 2A,B). The
WST cell proliferation assay was carried out to observe the
proliferation effect, which showed that the overexpression of
miR-33b significantly decreased cell proliferation as compared to
scramble in BT474 and SKBR3, and the inhibitory effects showed
a statistical significance after 7 days (Figures 2C,D). A recent
study showed that miR-33b regulates cell cycle and apoptosis
(23). To confirm this effect in our model, we evaluated apoptosis
by annexin-V. As shown in Figure 2E, the ectopic expression of
miR-33b induced early and late apoptosis in both HER2+ cell
lines. To verify these results, we further investigated the cell cycle
by PI/RNAse with miR-33b transfected cell lines, which showed a
considerable increase of cells in the sub-G0/G1 phase compared
to the control and a reduction almost by half in the number of
cells in G1 and S phases (Figure 2F). Collectively, it showed that
miR-33b has an anti-proliferative effect on HER2+ BC cell lines
and induced apoptosis with arrest of the cells at sub-G0/G1 phase.
Overexpression of miR-33b Suppresses
Invasion, Migration, EMT Process, and
Expression of EZH2 in HER2+ BC Cell
Lines
Tumor cell invasion and metastasis are tightly correlated with
various processes, including EMT. During EMT, epithelial cells
acquire mesenchymal characteristics with a high expression of
vimentin and ß-catenin, whereas the epithelial protein marker
CDH1 is downregulated. It has also been described that miR-
33b is a key regulator of MYC pathway, and one of the
downstream targets of this pathway is EZH2, which is a potential
regulator of cell proliferation, EMT, invasion, migration, and
drug resistance (24). The overexpression of miR-33b in BT474
induced a statistically significant increase of the expression of
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FIGURE 3 | miR-33b inhibits cell epithelial–mesenchymal transition, migration, and invasion in HER2+ cell lines. The relative expression of the EMT genes and
protein expression were checked after transfection with miR-NC and miR-33b in HER2+ cell lines: BT474 (A,B) and SKBR3 (C,D). SKBR3 cells were transfected
with miR-33b mimic, and cells penetrating the membrane were fixed with 0.4% crystal violet stain after 24 h to evaluate the invasion capacity (E). A wound healing
assay was performed on SKBR3 transfected with miR-33b to explore the migration properties of the cells. Black arrows indicate the wound edge. The relative
scratch gap was calculated as the percentage (%) of the remaining scratch gap at the given time point and the original gap at 0 h (F). Student’s t-test was used to
analyze the significant differences. **p < 0.01, ***p < 0.001.
CDH1 and significant decreases of ß-catenin, vimentin, and
EZH2 (Figure 3A). Consistent results were obtained with SKRB3
(Figure 3C). To confirm these data at the protein level, western
blot was performed (Figures 3B,D). However, CDH1 was unable
to detect SKBR3 because of its homozygous deletion of a large
portion of the gene in this cell line (25). Additionally, migration
and invasion assays were planned to explore the anti-metastatic
effect of miR-33b. The SKBR3 cells were transfected with miR-
33b mimic for 72 h and seeded on matrigel-based transwells to
check the invasion capacity within 24 h. The expression of the
mature miR-33b was confirmed by Q-PCR in that cell line (data
not shown). The results showed that the overexpression of miR-
33b induced a decrease in SKBR3 invasion capability compared
to the controls (Figure 3E). The migration process was carried
out by the wound healing assay. The results showed that miR-33b
overexpression significantly reduced the migration properties
of HER2+ cells compared to the negative control (Figure 3F).
Taken together, these results suggested that miR-33b inhibits cell
invasion and migration and acts as a possible crucial regulator of
the EMT process in HER2+ BC. Probably it can be an indirect
tumour aggressiveness inhibitory effects through targeting EZH2
in the specific BC subtype.
Inhibiting miR-33b Expression Induces
Cell Proliferation, Invasion, and
Migration in Non-tumorigenic Cells
Because the overexpression of miR-33b reduced cell proliferation,
invasion, migration, and EMT in HER2 + BC cell, we wondered
if inhibition of this miRNA in control cells would have the
opposite effect. To further investigate it, the miR-33b inhibitor
was transfected in control cell lines. The efficiency of transfection
was confirmed at 72 h post-transfection in both non-tumorigenic
cell lines (Figure 4A and Supplementary Figure 2A). WST assay
was carried out to evaluate the effect in proliferation, which
showed that inhibition of miR-33b increases the proliferation at
3 days as well as at 5 days in both control cell lines (Figure 4B
and Supplementary Figure 2B). After 72 h of transfection with
the miR-33b inhibitor, the cells were seeded on transwells to
evaluate the invasion (Figure 4C and Supplementary Figure 2C)
and the migration (Figure 4D and Supplementary Figure 2D)
properties of the cells. The results showed that inhibition of miR-
33b significantly promoted cell migration and invasion in both
non-tumorigenic cell lines. These data suggested that miR-33b is
required to control cell migration, invasion, and proliferation.
Downregulation of miR-33b Induces EMT
and EZH2 Expression
To better understand the molecular mechanism of action of miR-
33b on cell migration and invasion, we opted to explore the
regulation of EMT signaling and the regulation of EZH2. Control
cell lines were transfected with an inhibitor of miR-33b, and
at 72 h after transfection, EMT signaling pathway factors were
checked on the level of mRNA and protein expression. The results
showed that, with the inhibition of miR-33b, the expression of
CDH1 was significantly diminished, and there was an increase
of ß-catenin, vimentin, and EZH2 in both mRNA and protein
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FIGURE 4 | Inhibiting miR-33b induces cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) markers in non-tumorigenic breast cell
lines. Satisfactory transfection efficiency of miR-33b inhibitor in MCF-10A (A). Cell proliferation was carried out through WST assay in MCF-10A after transfection
with miR-33b inhibitor until 5 days (B). Reducing the expression of miR-33b increased the invasive (C) and the migration (D) abilities of MCF-10A. mRNA (E) and
protein (F) expression of the EMT markers using Q-PCR and western blot, respectively. Student’s t-test was used to analyze the significant differences. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
level (Figures 4E,F and Supplementary Figures 2E,F). Thus,
it supports that miR-33b can regulate EMT signaling in both
control and cancer cell lines.
Downregulation of EZH2 Inhibits
Proliferation in HER2+ BC Cell Lines
The previous results suggest that miR-33b is regulating EZH2. In
order to evaluate the role of EZH2 in HER2+ BC cell lines, BT474
and SKBR3 cells were transfected with two different si-EZH2.
Confirmation of gene and protein silencing was performed
by Q-PCR and by western blot, respectively. Both siRNAs
significantly inhibited EZH2 expression in BT474 and SKBR3
cells compared to controls (Figures 5A,B). To explore the effect
of silencing of EZH2 on cancer cell proliferation, the WST assay
showed that a lower expression of EZH2 significantly decreased
the cell proliferation in BT474 and SKBR3, and this inhibitory
effect showed statistical significance until 7 days (Figures 5C,D).
These results indicated that EZH2 may act as a crucial gene
for tumor aggressiveness in HER2+ BC through modulating
cell proliferation.
Downregulation of EZH2 Inhibits EMT,
Invasion, and Migration in HER2+ BC
Cell Lines
High levels of EZH2 have been involved in BC progression by the
regulation of the EMT process. To evaluate if the downregulation
of EZH2 mediates the inhibition of the EMT pathway in our
model, we silenced the EZH2 in BT474 and SKBR3 by two
different siRNAs to analyze the gene set enrichment of EMT. Both
cell lines were transfected with two specifically different siRNAs
of EZH2. The downregulation of the EMT genes was confirmed
by Q-PCR and the protein expression was evaluated by western
blot in both cell lines compared to the control (Figures 6A–D).
The results showed that the downregulation of EZH2 expression
induced a statistically significant increase of CDH1 and a decrease
of ß-catenin and vimentin in BT474 at both the mRNA and the
protein levels. There were no changes in ß-catenin (CTNNB1) at
the mRNA level in SKBR3 with the silencing of EZH2. However,
at the protein level, there was a reduction in the expression of ß-
catenin and vimentin at both the gene and the protein levels. In
addition, the silencing of EZH2 affects invasion and migration,
resulting in a decrease in the SKBR3 cell line (Figures 6E,F).
Altogether these results showed that EZH2 induces EMT to
promote invasion and migration in HER2 + BC cells.
High miR-33b Expression Levels Were
Correlated With Favorable Overall
Survival Outcome in HER2+ BC Patients
To assess the prognostic value of miR-33b and EZH2, we used
an in silico survival analysis of BC patients with the Kaplan–
Meier plotter. As a result, the BC patients with high miR-33b
expression showed a statistically significant improvement in
overall survival (OS) (p = 0.0246, HR = 0.76, 95% CI 0.60–
0.97) (Figure 7A), suggesting a good prognostic role of this
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FIGURE 5 | Reducing EZH2 expression induces proliferation in HER2 + cell lines. Q-PCR and Western blot results showing the gene silencing efficiency of siRNA
sequences targeting EZH2 using two silencers in BT474 (A) and SKBR3 (B) cell lines. Cell proliferation was carried out through WST assay in both cell lines, BT474
(C) and SKBR3 (D), after transfection with two different silencers until 7 days. Student’s t-test was used to analyze the significant differences. **p < 0.01,
***p < 0.001, ****p < 0.0001.
FIGURE 6 | Silencing EZH2 inhibits epithelial–mesenchymal transition (EMT) markers, invasion, and migration in HER2+ breast cancer cells. Q-PCR and western
blot results showing the EMT marker levels after silencing EZH2 in BT474 (A,B) and SKBR3 (C,D). Reducing the expression of EZH2 inhibits the invasive (E) and the
migration (F) abilities of SKBR3 cell. Student’s t-test was used to analyze the significant differences. *p < 0.05, ** p < 0.01, ***p < 0.001.
miRNA. The, opposite results were found with EZH2 when it was
evaluated among the same set of patients; it was observed that
a high expression was associated with a worse OS (p = 0.0095,
HR = 1.34, 95% CI 1.07–1.67) (Figure 7B). Similar results
were obtained in a cohort of HER2 + BC patients. We found
that a high miR-33b expression maintained a significant–good
prognosis in terms of OS (p = 0.039, HR = 0.74, 95% CI 0.55–0.99)
(Figure 7C). At the same time, high EZH2 expression showed
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FIGURE 7 | Prognostic value of miR-33b and EZH2 expression in breast cancer patients. In silico overall survival analysis of miR-33b (A) or EZH2 (B) in breast
cancer (BC) patients with Kaplan–Meier plotter. Survival analysis in a cohort of HER2+ BC patients: miR-33b (C) or EZH2 (D).
a poor prognosis (HR = 1.4, p = 0.13). Nevertheless, it was
not statistically significant, probably due to the low number of
subjects (Figure 7D). These results corroborated the importance
of this axis as a prognostic factor in HER2+ BC.
DISCUSSION
A lot of accumulated data have pointed out that several miRNAs
drive tumorigenesis and drug resistance and suppress cancer
progression by targeting different oncogenes (26). Although
multiple studies have been carried to study the roles of miRNAs
in BC, most of them have focused on BC in general and not on
the specific subtypes. HER2+ BC subtype is one of the cancers
with a worse prognosis and is associated with inferior outcomes
in survival (27), being an entity with a large heterogeneity
at multiple levels (28). In recent studies, miRNAs are being
identified as one of the key regulators to uncover the molecular
mechanisms of the heterogeneity in HER2 + BC.
The miR-33 family is one of the highly conserved miRNA
families that consists of two members: miR-33a and miR-
33b (29). They both act as a tumor suppressor in different
cancers such as non-small cell lung cancer (30), TNBC (31),
esophageal squamous cell carcinoma (32), and colorectal cancer
(33) via targeting EMT and proliferation. For the first time
in this study, we reported that miR-33b was downregulated in
breast HER2+ tumor samples when compared to normal breast
tissues and that the under-expression of miR-33b is related
to a poor prognosis in HER2+ patients. We also found that
miR-33b expression was higher in normal breast epithelial cell
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lines than in HER2+ BC cell lines. It has been described as
well that, in TNBC, miR-33b represses cancer progression and
metastasis by targeting oncogenes like SALL4, TWIST1, and
HMGA2 (13). These data indicate that miR-33b acts as an onco-
suppressive miRNA in BC progression. To investigate the specific
mechanism of miR-33b in HER2+ BC progression, miR-33b was
ectopically overexpressed in different HER2+ cell lines, where it
was shown that the upregulation of this miRNA inhibits cancer
cell invasion and migration. As it has been already reported that
this miRNA regulates EMT (34), we here demonstrated that the
overexpression of miR-33b inhibits the EMT process in HER2+
subtype of BC by regulating EZH2 expression. Furthermore,
we reported that the overexpression of miR-33b has an impact
on cell proliferation and induces apoptosis in this BC subtype.
Besides that, this miRNA also arrests the cell cycle in the sub-
G0/G1 phase as compared with the other phases, which is in
concordance with previous results in lung cancer (8). Recently,
some authors suggested that miR-33a can regulate EZH2 by
their direct interaction (21). We checked in silico the physical
interaction between miR-33b and EZH2 in Targetscan, miRDB-
MicroRNA Target Prediction Database, miRNet, miRTarBase,
miRanda databases, and the Freiburg RNA tools. In the latter
case, we found an interaction with a yield of very low energy.
Based on this information, we performed the luciferase assay
and we found that there is no such direct interaction between
miR-33b and EZH2 (data not shown), which clarified that
although miR-33a and miR-33b belong to the same family, they
regulate the same gene in a different way. It has been previously
demonstrated that MYC binds to the EZH2 promoter and directly
activates its transcription (20). Besides that, EZH2 expression
is positively correlated with MYC expression in prostate cancer
(35). Moreover, it has been already described that MYC is a direct
target of miR-33b (10). Thus, in our present study, we showed
that the ectopic overexpression of miR-33b regulates MYC in
our models (Supplementary Figures 3A–D) and the sequences
of miR-33b have binding sites within the human MYC 3′UTRs
(TargetScan can, Supplementary Figure 3E). Considering all
these, we suggest EZH2 as a target of miR-33b via regulating the
MYC (Supplementary Figure 3F).
Epithelial–mesenchymal transition is a crucial process during
the development of tumorigenesis and metastasis. Enormous
evidences indicate that EMT is responsible for cancer cell
invasion and migration and an initial step of metastasis. EZH2
is reported to be upregulated in aggressive BC (36) and involved
in epigenetic, post-translational modifications and EMT program
by suppressing CDH1 expression (37). In nasopharyngeal
carcinoma, miR-142-3p was downregulated by DNA methylation
due to EZH2’s recruitment of DNMT1 which occupied the
upstream region of the miR-142 and determined ZEB2 activation,
leading to EMT and metastasis (38). Furthermore, EZH2 is
a direct target of miR-26a in docetaxel resistance cells, which
could significantly suppress proliferation, facilitate apoptosis,
inhibit the metastasis ability, and reverse EMT to mesenchymal–
epithelial transition in lung adenocarcinoma cells (39). In
oral tongue squamous cell carcinoma, miR-101 inhibits the
expression of EZH2 via two transcription factors, Snail and Slug
(40). In BC, miR-92b may negatively regulate the expression
of EZH2, promoting autophagy and decreasing tumor cell
viability, migration, and invasion (41). Additionally, miR-139-
5p transcription is inhibited by EZH2 through upregulating
H3K27me3; thereby, the downregulation of EZH2 and the
upregulation of miR-139-5p impede EMT in lymph node
metastasis pancreatic cancer (42). Accumulating all these
summarized results, the expression of EZH2 is upregulated in
different types of cancer, and its inhibition is required by different
miRNAs and drugs to reduce cancer progression. Given that
the behavior of EZH2 is context dependent, in this study we
investigated the role of EZH2 specifically in HER2+ BC. In our
study, we determined that EZH2 is highly expressed in HER2+
BC cell lines as well as in solid tumors in comparison with
normal epithelial cell line and normal breast tissue which show an
inverse correlation. To dig more on the molecular mechanisms
of EZH2, it has been silenced through two different silencers in
BC cell lines, which resulted in the inhibition of cell proliferation,
migration, invasion, and EMT in HER2+ BC cells, confirming
that EZH2 expression has a crucial role in HER2+ BC progression
(Supplementary Figure 3F). Future in vivo experiments to
evaluate the role of miR-33b in HER2+ BC metastasis are needed.
In summary, EZH2 might be an important factor of HER2+
BC progression and associated with a decrease in the overall
survival of patients since EMT has been critically discussed as
the key process in tumor aggressiveness and metastasis (43).
Our findings in the present study demonstrate for the first time
that miR-33b acts as a suppressive miRNA in HER2+ BC, which
could inhibit tumor migration and invasion partly by impeding
EMT through the repression of the MYC–EZH2 loop. This study
suggests a novel miR-33b/MYC/EZH2 axis that modulates the
growth and the progression of breast cells and could be clinically
useful to design new drugs against HER2+ subtype cancer.
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